Tryptyr
(Acoltremon)ApprovedSmall molecule
This eye drop medication is used to treat dry eye disease by stimulating the eyes to produce more tears, helping to restore adequate moisture to the eyes.[2] Tryptyr is currently approved and in use across 2 indications[4].[1]
Tryptyr is one of 29 small molecule programs targeting Eye Disease. It is currently in Approved.
2
Indications
2
Total Trials
2
Active Trials
28
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
5
Patents
Pipeline
Status by Indication[4][1]
Competition
Competitive Landscape
29 competitors in Eye Disease
#DrugCompanyPhaseTrials
1Chantix
PPrism Pharmaceuticals
Approved
Empaveli
Apellis PharmaceuticalsApproved
Rapamune
PPrism Pharmaceuticals
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Heparin Sodium
BBaxter Healthcare Corporation
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Tryptyr
FFalcon
Approved
Miebo
BBausch & Lomb Incorporated
Phase 3
AZR-MD-001
AAzura Ophthalmics
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[5]
May 28, 2025
TRYPTYR
NDA NDA217370
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tryptyr drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Acoltremon. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]